



2017 Updates to Target: Heart Failure

July 20, 2017

Presenter: Gregg C. Fonarow, MD, FACC, FAHA



TARGET:HF™

Our Presenter



Gregg C. Fonarow, MD, FACC, FAHA

The Eliot Corday Professor of Cardiovascular Medicine and Science
Co-Chief of Clinical Cardiology UCLA Division of Cardiology
Director, Ahmanson-UCLA Cardiomyopathy Center
Co-Director, UCLA Preventative Cardiology Program

Disclosures

- Research NIH
- Consultant Amgen
- Janssen
- Medtronic
- Novartis
- St. Jude Medical

Target:HF Overview

What Is Target: HF?

- Launched in 2011, A national initiative of the American Heart Association within GWTG HF that focuses on targeted area that provides healthcare professionals with content-rich resources and materials designed to help advance heart failure awareness, prevention, and treatment.

Target: Heart Failure Mission:

Increase 3 key patient-centered care domains with very well established or emerging evidence-base:

- *Medication optimization*
- *Early follow-up and care coordination*
- *Enhanced patient education*

Get With The Guidelines® - Heart Failure Overview

- Get With The Guidelines®- Heart Failure launched in 2005
- 4 Achievement Measures and 10 Quality Measures
- Hospitals enrolled have several opportunities to be recognized for their efforts and are recognized at National events
- As of June 2017, there are greater than 87 Get With The Guidelines manuscripts focused on Heart Failure.
 - Publications are viewable at www.heart.org
- 684 Hospitals enrolled in the program
- Over 1,500,000 patients entered into the PMT

Most Comprehensive Measure Set Available

Achievement Measures

- ACEI/ARBs or ARNi at Discharge*
- Evidence-Based Specific Beta Blockers*
- Measure LV Function
- Post-Discharge Appointment for Heart Failure Patients

Quality Measures

- ARNi at Discharge
- Aldosterone Antagonist at Discharge*
- Anticoagulation for Atrial Fibrillation and Atrial Flutter
- Hydralazine Nitrate at Discharge
- DVT Prophylaxis
- CRT-D or CRT-P Placed or Prescribed at Discharge
- ICD Counseling Provided or Prescribed or Placed at Discharge
- Influenza Vaccination During Flu Season
- Pneumococcal Vaccination
- Follow-Up Visit Scheduled Within 7 Days or Less

Reporting Measures

- Blood Pressure Control at Discharge
- Beta Blocker at Discharge
- Beta Blocker Medication at Discharge
- Lipid-Lowering Medications at Discharge
- Omega-3 Fatty Acid Supplement Use at Discharge
- Diabetes Treatment
- Diabetes Teaching
- Smoking Cessation
- Discharge Instructions
- ICD Placed or Prescribed at Discharge
- Advanced Care Plan
- QRS Duration Documented
- Heart Failure Disease Management Program Referral
- Follow-Up Visit or Contact Within 48 Hours of Discharge Scheduled

Most Comprehensive Measure Set Available

Reporting Measures (*Continued*)

- Follow Up Visit or Contact Within 72 Hours of Discharge Scheduled
- 60 Minutes of Heart Failure Education
- Referral to AHA Heart Failure Interactive Workbook
- Referral to HF Disease Management, 60 Minutes Patient Education, Or HF Interactive Workbook*
- Heart Failure Activity Level
- Heart Failure Diet
- Heart Failure Follow-Up
- Heart Failure Weight
- Heart Failure Symptoms Worsen
- Length of Stay
- Care Transition Record Transmitted
- Advance Directive Executed
- Discharge Disposition
- Ivabradine Prescribed

Descriptive Measures

- Age
- Diagnosis
- Gender
- Race
- HF Composite Measure
- HF Defect-Free Measure
- JC/CMS HF Defect Free Measure
- Target: HF Defect Free Measure

Mortality & Readmission Measures

- In-Hospital Mortality
- Risk Adjusted Mortality Ratio
- Readmission Frequency & Rate
- 30, 60 & 90 Day Readmissions & Rate
 - *Not equivalent to the CMS 30-Day Risk-Standardized Readmission Measure. It is not risk-adjusted, does not represent all cause readmission, and does not capture readmissions from other hospitals.*

Target: HF Award Recognition Measures

- Discharge use of ACEI/ARB or ARNi
- Evidence-based beta blocker
- Aldosterone antagonist (In all eligible heart failure patients with reduced LVEF, in absence of documented contraindications, intolerance, or patient/system reasons)
- Early post-discharge follow-up with visit or phone call scheduled to occur within 7 days of hospital discharge
- **UPDATED**: Enhanced patient education as evidenced by referral to heart failure disease management program, provision of at least 60 minutes of heart failure education by a qualified heart failure educator, or provision of AHA heart failure interactive workbook **OR were referred to an outpatient cardiac rehabilitation program**

Updated recognition measure available in the PMT Spring 2018

Target: Heart Failure Honor Roll Recognition

Requirements: Documentation of all three care components for **50% or greater of compliance** for eligible patients with heart failure.


Hospitals must be GWTG-HF performance achievement award hospitals.

Target:HF Honor Roll 2011 to 2017

■ 2012 ■ 2013 ■ 2014 ■ 2015 ■ 2016 ■ 2017


438 Total Awards
to date

192 Hospitals Awarded
to date




Target:HF Honor Roll


GWTG-HF: Achievement Measures (1)




GWTG-HF: Achievement Measures (2)




GWTG-HF: Achievement Measures (3)




GWTG-HF: Quality Measures (1)




GWTG-HF: Quality Measures (2)



GWTG-HF: Quality Measures (3)



GWTG-HF: Quality Measures (4)



Program Updates

Objectives of the Update

- Re-brand Get With The Guidelines Target: Heart Failure
- Enhance clinical tools to be reflective of the 2013 HF Guidelines, and updates in 2016 and 2017
- Launch *OnTarget*, a monthly newsletter featuring clinical resources and on key program elements
- Update the main website heart.org/targethf with updated branding
- Launch the Target:HF App to bring key clinical resources to your mobile device

Taking Action

- National Heart Failure Clinical Work Group members met to review and assess the program
- Conducted a review of all existing materials and provided updates to the clinical tools
- Materials were updated and went through a thorough AHA science review
- Updates made are reflective of the *2013 ACCF/AHA Guideline for the Management of Heart Failure* and the updates released in 2016 and 2017

Taking Action

- Enhancements to clinical tools include:
 - Medication updates including ARNi and Ivabradine
 - Inclusion of the LACE+ risk score as an additional clinical tool
 - Updated Target:HF Composite measure to include Cardiac Rehab
 - Updated patient readmission risk factor, medication adherence and cardiac rehab
 - Updated list of factors of readmission to include patient factors such as: frailty, cognition/memory, social support and language barriers, etc.

Update to Target:HF Composite Measure

Referral to HF Disease Management, 60 Minutes Patient Education, HF Interactive Workbook or Referral to Outpatient Cardiac Rehabilitation Program

Percent of heart failure patients who were referred to heart failure disease management, received 60 minutes of patient education by a qualified educator, received an AHA heart failure interactive workbook, or were referred to an outpatient cardiac rehabilitation program

Exclusions: (Always remove from denominator)

- Comfort Measures only documented
- Patients transferred to another acute care hospital; patients discharged/transferred to a Designated Cancer Center or Children's Hospital; patients who expired; patients who expired in medical facility; patients who left against medical advice; patients discharged to hospice; patients discharged to a federal hospital; patients discharged/transferred to a critical access hospital (CAH)
- Patients for whom disease management is not applicable
- Patients for whom 60 minutes of HF education is not applicable
- Patients for whom referral to AHA heart failure interactive workbook is not applicable
- Patients for whom referral to Outpatient Cardiac Rehabilitation Program is not applicable

Numerator

Heart failure patients who were referred a disease management program OR received 60 minutes of patient education by a qualified educator, OR received an AHA heart failure interactive workbook OR were referred to an outpatient cardiac rehabilitation program

Taking Action Updated Collateral

TARGET:HF™

THE FACTS ABOUT HEART FAILURE

THE PROBLEM

1 IN 8 DEATHS HAS HEART FAILURE MENTIONED ON THE DEATH CERTIFICATE

50% OF PEOPLE DIAGNOSED WITH HEART FAILURE WILL DIE WITHIN FIVE YEARS

THE LIFETIME RISK OF HF OCCURRING FOR PEOPLE WITH A BP GREATER THAN 160/90 IS 1.6 TIMES THAT OF THOSE WITH BLOOD PRESSURE LESS THAN 120/90 MM HG

IN THE GWTC-HF REGISTRY, ONLY ONE TENTH OF ELIGIBLE HF PATIENTS RECEIVED CARDIAC REHABILITATION REFERRAL AT DISCHARGE AFTER HOSPITALIZATION FOR HF

AMONG MEDICARE PART D

TARGET:HF™

REDUCING 30-DAY READMISSIONS THROUGH ENCOURAGEMENT, EDUCATION AND EXPERIENCE.

ENCOURAGEMENT

Every heart failure is a fight. Every recovery is a win. And every patient that stays healthy is a victory worth celebrating.

EDUCATION

The Target:Heart Failure initiative is helping lead the fight by providing healthcare professionals with custom risk resources and materials designed to help advance heart failure awareness, prevention and treatment.

EXPERIENCE

Target:Heart Failure strives to improve quality, care transitions, and outcomes for patients with heart failure utilizing patient-centered domains and leveraging the American Heart Association's premier quality improvement suite of resources including Get With The Guidelines-Heart Failure.

REDUCE READMISSIONS

With Target:Heart Failure, your hospital will increase the likelihood of better quality of life for your patient and reduced 30-day readmissions through Medication Optimization, Early Follow-up Care and Coordination and Enhanced Patient Education.

JOIN THE FIGHT

Participation in Target:Heart Failure means you will be contributing to focus on a patient population that is in constant need of increased education and discovering new ways to manage their chronic condition. Anyone can participate in Target:Heart Failure. Simply register at www.heart.org/target and click the link on the home page.

HEART FAILURE QUALITY MEASURE SET

Target:Heart Failure's goal is to improve quality, care transitions, and outcomes for patients with heart failure utilizing patient-centered domains and leveraging the American Heart Association's premier quality improvement suite of resources including Get With The Guidelines-Heart Failure.

ACHIEVEMENT MEASURES

- ACEI/ARB or Discharge (within 48h)
- Evidence-based Specific Beta Blocker
- Medication D Function
- Risk Discharge Agreement for Heart Failure Patients

QUALITY MEASURES

- HFRA at Discharge (Heart)
- Aliskiren/Angiotensin at Discharge and Fluid Status
- Hydralazine Home at Discharge
- DD Treatment
- OTIS or OTIS Fluid at Discharge

REPORTING MEASURES

- Intravenous at Discharge (Heart)
- Blood Pressure Control at Discharge
- Stable Renal Function at Discharge
- Stable Sodium Medication at Discharge
- Liquid Limiting Medication at Discharge
- Change in Medication Supplement
- Time at Discharge

TARGET:HF™

HEART FAILURE DISCHARGE CHECKLIST

Please complete all boxes for each HF indicator:

Admit Date: _____ Admit Unit: _____ Discharge Date: _____ Discharge Unit: _____
 Attending Physician: _____ HF Etiology: _____
 Follow-up appointment (date/time/location): _____

Complete All Boxes for Each HF Indicator	YES	NO	Reason Not Done/Contraindications
Angiotensin-converting enzyme inhibitor (if LVSD)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Angiotensin receptor blocker (if LVSD and ACEI not tolerated)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Angiotensin receptor/neprilysin inhibitor (if LVSD, and in place of an ACEI or ARB)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
β-Blocker (if LVSD, use only carvedilol, metoprolol succinate, or bisoprolol)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Alosterone antagonist (if LVSD, Cr < 2.5 mg/dL in men, < 2.0 mg/dL in women, potassium < 3.5 mg/dL, and patient's potassium and renal function will be closely monitored)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Hydrochlorothiazide (if self-identified African American and LVSD)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Most recent left ventricular ejection fraction (____%)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Date of most recent LVF (____)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Method of assessment: <input type="checkbox"/> Echocardiogram <input type="checkbox"/> Cardiac catheterization <input type="checkbox"/> MUGA scan	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Anticoagulation for atrial fibrillation or flutter (permanent or paroxysmal) or other indications	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Precipitating factors for HF decompensation identified and addressed	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Blood pressure controlled (<140/90 mm Hg)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Pneumococcal vaccination administered	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
Influenza vaccination administered (during 12 weeks)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI
EP consult if sudden death risk or potential candidate for device therapy	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/> NA <input type="checkbox"/> CI

Patient Sticker Here

TARGET:HF™

Heart Failure 30-day Readmission Risk Calculator

Adults with heart failure are at high risk for early rehospitalization. This risk may vary by patient, heart failure and provider characteristics. Clinical risk tools may help to stratify risk.

The Yale risk calculator can help predict heart failure 30-day readmission:

The Center for Outcome Research and Evaluation (CORE) released an online readmission risk calculator for heart failure.

You can view the CORE risk calculator at http://readmissioncore.org/heart_failure.php

The online readmission risk calculator can help predict a patient's likelihood of hospital readmission for heart failure within 30 days of discharge. Despite the benefits of the heart failure readmission calculation, there are some limitations worth noting:

- This tool provides only an estimate of risk for readmission.

- The tool assumes that the performance of the treating hospital is average in terms they did not seek to limit the number of variables (as the calculation does) or to include information about in-hospital.

- When CORE developed the risk adjustment model, adverse events.

- The calculator does not provide guidance on how to use the estimates.

Despite these limitations, the risk calculator can provide hospitals with valuable insights regarding possible readmission.

Hospitals should consider what transition care/care coordination strategies they should deploy to decrease 30-day readmission. Target:Heart Failure offers many tools and resources to hospitals.

Find out what's available at heart.org/target

TAKING THE FAILURE OUT OF HEART FAILURE



TARGET:HF

TARGET:HF™

GENERAL INFORMATION

Discharge date: (mm/dd/yyyy) _____
 Patient name: _____
 Date of birth: (mm/dd/yyyy) _____
 Primary care physician: _____
 Cardiology: YES NO Assisted Care? YES NO
 Labs ordered/done prior to first follow up call or appointment? YES NO
 Date: (mm/dd/yyyy) _____

PATIENT EDUCATION

INTRODUCTION: My name is _____ I am calling from (INSERT HOSPITAL NAME). I am doing a follow-up _____
 country's call to see how you are doing.

Weight monitoring
 Do you have a scale at home that you can use to weigh yourself? YES NO
 If patient answered no, advise the patient to buy a scale YES NO
 If patient answered yes to having a scale YES NO
 Can you see the numbers on the scale? YES NO
 Have you been weighing yourself daily? YES NO

Dry weight (at home, 1st day after discharge)
 Did you take your dry weight 1 day after discharge? YES NO
 Do you have a weight diary? YES NO

If no, was the patient provided with a weight calendar during this visit? YES NO

Do you understand how and when to check your weight? YES NO

TARGET:HF™

Discharge Criteria for Patients Hospitalized with Heart Failure

Recommended for all adult patients with heart failure.

- Precipitating and exacerbating factors addressed
- Transition from intravenous to oral diuretic successfully
- Near optimal/ optimal volume status achieved
- Near optimal/ optimal pharmacologic therapy for heart failure
- Stable renal function and electrolytes within normal range/ near normal range based on patient's baseline
- No symptomatic supine or standing hypotension or dizziness
- Patient and family education completed
- Details regarding medications and medication reconciliation
- Need for medication adherence understood by patient/family
- Dietary sodium restriction and understands rationale for adherence
- Need for daily activity and exercise, and under stands rationale for both
- Need for monitoring of daily weights and when to contact provider
- Plan to reassess volume status early after discharge is documented (when/where)
- Plan to monitor electrolytes and renal function early after discharge is documented (what/when)
- Plan to titrate heart failure medications to target dose, if needed, is documented (what/when)
- Plan to reinforce patient and family education post-discharge is documented (when/where/ themes)
- Follow-up clinic visit scheduled within 7 days of hospital discharge is documented (when/where/ with whom)
- Follow-up phone call scheduled in addition to clinic visit is documented (when)
- Referral to outpatient cardiac rehab program

- Oral medication regimen, stable for at least 24 hours
- No intravenous vasodilator or inotropic agent for at least 24 hours
- Ambulation before discharge to assess functional capacity
- Careful observation before and after discharge for worsening, or development of, renal dysfunction, electrolyte abnormalities and symptomatic hypotension
- Plans for more intensive post-discharge management (scale present in home, visiting nurse, or telephone follow-up no longer than 3 days after discharge)
- Referral for formal heart failure disease management

This is a general algorithm to assist in the management of patients. This clinical tool is not intended to replace individual medical judgment or individual patient needs.

TAKING THE FAILURE OUT OF HEART FAILURE



TARGET:HF

Identifying Avenues for Growth

- Conducted in-depth telephone interviews with active Target: HF customers
- A qualitative discussion guide was used focusing on:
 - Challenges associated with caring for heart failure patients
 - Target HF program awareness and benefits
 - HF resources currently used
 - Website feedback
 - Communication preferences
- Assessed hospital needs for resources to support their efforts to treat heart failure and lower readmission rates.
- Determined availability of resources for hospitals, and identify how Target: HF fills the gap.
- Assessed current program look and feel, programmatic, marketing, and communications elements

Identifying Avenues for Growth

Target: HF Customer Survey - Insight on Metrics

- General consensus is the right metrics are in place, and that they are helpful in keeping the focus on the patient (rather than hospital process)
- Most frequently discussed metrics were evidence-based beta blockers, in-hospital education, and scheduling follow-up appointments
- Those within the Quality area spoke to the need for more powerful data mining software to allow for more detailed/customized extractions and aggregations
- Ability for EHR information to automatically flow into Get With The Guidelines so less time is spent on chart extractions

Connecting with a Wider Audience

On Target Newsletter Series

- Emailed monthly
- Highlights key-topics in improving 30-day rehospitalization rates
- Special 3 month focus on medication adherence including: ACE/ARB or ARNI, Evidence-based beta blockers, Aldosterone Antagonist
- Featured Clinical Tools and Resources

To receive OnTarget, email, liz.olson@heart.org



Website Updates

- Heart.org/targethf
- New look launching in the coming month
- Refreshed look and feel.
- Revised navigation
- Easier to access key program materials, research and patient education resources





INTRODUCING! Target: HF App

- Progressive Web App
- Interactive mobile site – designed for mobile use
- Dedicated link targethf.heart.org (COMING SOON)
- Ability to save to home screen
- Adaptability for phone, tablet users
- Accessible from computer
- Includes the Yale Risk Calculator and LACE+ Calculator; input data right from your phone, tablet
- Key clinical topics in heart failure featured in our media area
- Editable PDF clinical tools
- Clinical Tools editable in-app with CSV email




Target: HF App

Home Screen and Menu



Target: HF App

Clinical Tools



- All clinical tools updated with the latest science.
- Fast, easy access to our most valuable clinical Tools
- Documents available in English and Spanish
- New resources for patient education in cardiac rehab, medication adherence and more
- Links to *Rise Above HF* initiative
- Updated Interactive Workbook “MY HF GUIDE” accessible from the app on your phone or tablet



Target: HF App

Webinar Recordings



Outlook • LTE 1:07 PM 80%

targethf.wpengine.com

WARNING SIGNS

TARGET:HF MENU

Media

Transitions of Care

Clinical Predictors of 30-Day Rehospitalization

Factors	GWTC-HF: N=33,349 ¹	Medicaid Pts: N=4548 ²	Elders N=2176 ³	Alberta CA N=18,590 ⁴
Abnormal troponin	1.15 (1.1-1.2)			
Black race (vs. white)	1.11 (1.0-1.2)			
creatinine-Kid. Dis.	1.12 (1.1-1.2)	1.45 (1.1-1.9)	1.72 (1.3-2.2)	1.43 (1.2-1.7)
Medicaid (vs. comm.)		1.68 (1.3-2.2)		
Prior adm. < 1 yr.			1.25 (1.1-1.5)	
Diabetes			1.17 (0.9-1.4)	
Atrial Fibrillation				1.14 (1.0-1.3)
Age ≥ 75 yrs				1.43 (1.0-2.0)

58:20

- Featuring important topics in the management of Heart Failure
- Archive of past national AHA GWTC-HF and Target:HF webinars
- Viewable in app on your mobile phone or tablet
- Future updates will include bonus video and audio content not available on heart.org

Target: HF App

LACE+ Calculator

AT&T LTE 4:45 PM 60%

targethf.wpengine.com

GENDER

MALE

ACUITY OF ADMISSION

URGENT (OR EMERGENCY) ADMISSION

TEACHING STATUS of the hospital

Teaching hospital

LENGTH OF STAY

*Time between when the patient is first marked with a base class of inpatient and Discharge.
i.e. Does not include time spent in ED prior to inpatient admission.*

< 1

ALC (Alternative Level of Care) days during admission

Patient is admitted but not receiving active medical care

ALC DAYS = 0 ALC DAYS > 0

ED VISITS in Previous 6 Months

Does not include ED visits that later become an admission because the patient class of Emergency would no longer apply

ED VISITS = 0 ED VISITS = 1 ED VISITS > 1

LACE+ Calculator

Your LACE+ Index

72

LACE+ Risk Stratification	LACE+Score
Highest Risk (Hot Pink)	79 - 90
High Risk (Red)	59 - 78
Moderate Risk (Yellow)	29 - 58
Minimal Risk (Green)	0 - 28

The LACE index (score 0-19) uses 4 variables to predict the risk of death or urgent readmission within 30 days after hospital discharge: LOS (**L**), acuity of admission (**A**), comorbidity (**C**) and ED visits in previous 6 months (**E**).

The LACE+ Index (score 0- 90) is a modified version of the LACE Index in which each patient receives a score based on all the same parameters used by LACE, as well as the following: age; gender; teaching status of the hospital; number of days on alternative level of care during admission; number of elective admissions in previous year; number of urgent admissions in previous year.



Special thanks to our Target:HF sponsor
Novartis Pharmaceuticals



*Novartis Pharmaceuticals Corporation is a national sponsor of
American Heart Association's Target: Heart Failure.*

Contact Us to Learn More

Steve Dentel BSN, RN, CPHQ

National Director, Field Programs and Integration

steve.dentel@heart.org

GWTG-Heart Failure

Tanya Lane Truitt, RN MS

Sr. Program Manager *Quality Systems Improvement*

tanya.truitt@heart.org

Liz Olson

Program Manager, *Get With The Guidelines – Heart Failure*

liz.olson@heart.org

Stay informed on the latest updates from Get With The Guidelines

[Sign Up for Focus on Quality e-Communications](#)

THANK YOU
for your active participation and
contributions to GWTG-HF



TARGET:HF™

The "TARGET:HF" logo features the word "TARGET" in a standard sans-serif font, followed by a colon and the letters "HF" in a significantly larger, bold, sans-serif font. A registered trademark symbol is located at the end of the text.